PROQR THERAPEUTICS NV (PRQR) Stock Price, Forecast & Analysis
NASDAQ:PRQR • NL0010872495
PRQR Key Statistics, Chart & Performance
The current stock price of PRQR is 1.59 USD. In the past month the price decreased by -0.62%. In the past year, price decreased by -31.76%.
PRQR Technical Analysis
PRQR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PRQR. Both the profitability and financial health of PRQR have multiple concerns.
PRQR Financial Highlights
Over the last trailing twelve months PRQR reported a non-GAAP Earnings per Share(EPS) of -0.49. The EPS decreased by -42.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.23% | ||
| ROE | -74.59% | ||
| Debt/Equity | 0.18 |
PRQR Forecast & Estimates
15 analysts have analysed PRQR and the average price target is 9.18 USD. This implies a price increase of 477.36% is expected in the next year compared to the current price of 1.59.
For the next year, analysts expect an EPS growth of -39.17% and a revenue growth -24.87% for PRQR
PRQR Ownership
PRQR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.98 | 397.113B | ||
| AMGN | AMGEN INC | 17.23 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.7 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.37 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.7 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.61 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.1 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PRQR
Company Profile
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 166 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Company Info
PROQR THERAPEUTICS NV
Zernikedreef 9
Leiden ZUID-HOLLAND 2333 CK NL
CEO: Daniel de Boer
Employees: 166
Phone: 31881667000
PROQR THERAPEUTICS NV / PRQR FAQ
What does PROQR THERAPEUTICS NV do?
ProQR Therapeutics NV is a clinical stage biopharmaceutical company, which engages in the discovery and development of RNA therapies for the treatment of severe genetic rare diseases with a focus on inherited retinal diseases. The company is headquartered in Leiden, Zuid-Holland and currently employs 166 full-time employees. The company went IPO on 2014-09-18. The firm is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The firm operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Can you provide the latest stock price for PROQR THERAPEUTICS NV?
The current stock price of PRQR is 1.59 USD.
Does PRQR stock pay dividends?
PRQR does not pay a dividend.
What is the ChartMill technical and fundamental rating of PRQR stock?
PRQR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the PE ratio for PRQR stock?
PROQR THERAPEUTICS NV (PRQR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.49).
Can you provide the growth outlook for PROQR THERAPEUTICS NV?
The Revenue of PROQR THERAPEUTICS NV (PRQR) is expected to decline by -24.87% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.